MENDUS ABMENDUS ABMENDUS AB

MENDUS AB

No trades
See on Supercharts

IMMU fundamentals

Key facts

Market capitalization
Founded
CEO
Website
About

Mendus AB is a clinical-level biopharmaceutical company, which engages in the provision of allogeneic dendritic cell biology focused on the development of immunotherapies that address tumor recurrence and hard-to-treat established tumors. It operates under the Sweden and Netherlands geographic segments. The company was founded by Bengt Anders Andersson, Alex Karlsson-Parra, and AnnaCarin Wallgren in 2002 and is headquartered in Stockholm, Sweden.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

IMMU does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company